Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

Phase 2CompletedNCT00262483

Vertex Pharmaceuticals Incorporated12 enrolled

Overview

To assess the safety of the combination of VX-950, Pegasys and Copegus in subjects with hepatitis C.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Masking

NONE

Enrollment

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Infected with hepatitis C virus Exclusion Criteria: * Contraindications to peginterferon or ribavirin therapy.

Call for information

San Antonio, Texas, United States

Call for information

Santurce, Puerto Rico

Safety of triple combination therapy.

Time frame: retrospective and prospective

Pharmacokinetics of VX-950, peginterferon alfa-2a and ribavirin.

Time frame: retrospective and prospective

Plasma HCV RNA levels

Time frame: retrospective and prospective

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.